XML 54 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of the Net Purchase Price and Allocation to the Acquired Assets (Detail) - ProstaGene, LLC - USD ($)
Nov. 16, 2018
Nov. 30, 2018
Business Acquisition, Contingent Consideration [Line Items]    
CytoDyn Inc. Equity $ 11,558,000  
Acquisition Expenses 741,297  
Release of Deferred Tax Asset 2,826,919  
Total Cost of Acquisition 15,126,216  
Intangible assets 15,126,216 $ 15,126,216
Other 0  
Allocation of Acquisition Costs $ 15,126,216